This confirms previous observations indicating that TTFields are efficient in GBM regardless of the MGMT methylation status [10, 65] and indicates that Pem could also benefit MGMT un-methylated GBM patients, known to be more resistant to TMZ. The gene discussed is MGMT; the disease is glioblastoma.